Caprock Group LLC Purchases Shares of 53,461 Takeda Pharmaceutical Co. $TAK

Caprock Group LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 53,461 shares of the company’s stock, valued at approximately $801,000.

A number of other institutional investors also recently modified their holdings of the stock. Advisors Asset Management Inc. boosted its stake in Takeda Pharmaceutical by 11.6% during the third quarter. Advisors Asset Management Inc. now owns 42,424 shares of the company’s stock worth $621,000 after acquiring an additional 4,395 shares in the last quarter. ABC Arbitrage SA acquired a new position in shares of Takeda Pharmaceutical during the third quarter valued at about $8,372,000. Smartleaf Asset Management LLC boosted its position in shares of Takeda Pharmaceutical by 83.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 19,895 shares of the company’s stock worth $291,000 after purchasing an additional 9,066 shares in the last quarter. Gallacher Capital Management LLC grew its stake in shares of Takeda Pharmaceutical by 23.8% in the 3rd quarter. Gallacher Capital Management LLC now owns 27,245 shares of the company’s stock valued at $399,000 after buying an additional 5,245 shares during the period. Finally, Savant Capital LLC grew its stake in shares of Takeda Pharmaceutical by 14.7% in the 3rd quarter. Savant Capital LLC now owns 37,640 shares of the company’s stock valued at $551,000 after buying an additional 4,816 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Finally, Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating for the company. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.6%

NYSE TAK opened at $18.49 on Monday. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $16.12 and a 200 day simple moving average of $15.06. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.50. The firm has a market capitalization of $58.82 billion, a P/E ratio of 77.02 and a beta of 0.02.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.40. The firm had revenue of $6.75 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. On average, analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.